There may be some confusion here. *Atl-1103 blocks growth...

There may be some confusion here.

*Atl-1103 blocks growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin‐like growth factor‐I (IGF‐I).
*Atl-1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (very late antigen-4)

The Toxicity study is only relative to Atl-1102, in particular for PML which correlates to situations where VLA-4 has been targetted.

My guess is Atl-1102 for MS will be revitalised after a successful tox study which will hopefully align with better finances provided by some deals re DMD, or via a biotech association of some sort.
Atl-1103 is on the back burner till more funds are available to further the development and market the product appropriately.

DMD (if successful) is the lynchpin or the pivot point to funding anything and everything, so all focus is there, primarily for now.
Successful toxicology results open numerous doors for all things Atl-1102.